Key Dates

Related Announcements

PAR-22-212 - Institutional Research and Academic Career Development Awards (IRACDA) (K12 - Independent Clinical Trial Not Allowed)

Issued by

National Institute of General Medical Sciences (NIGMS)

Purpose

The purpose of this Notice is to alert potential applicants of a clarification in the "Eligible Organizations" section of PAR-22-212 "Institutional Research and Academic Career Development Awards (IRACDA) (K12 - Independent Clinical Trial Not Allowed)" regarding the eligibility of institutions with multiple campuses.

Part 2. Section III.3. Additional Information on Eligibility

Currently reads:

Number of Applications

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per 2.3.7.4 Submission of Resubmission. This means that the NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
• An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Only one application per institution (normally identified by having a unique NIH Institutional Profile Number, IPF) is allowed. An institution may hold only one IRACDA grant award.

The IRACDA award may not be transferred from one institution to another.    

Modified to read (changes in italics):

Number of Applications

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per 2.3.7.4 Submission of Resubmission. This means that the NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
• An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Only one application per applicant organization (normally identified by having a Unique Entity Identifier (UEI) and a unique NIH Institutional Profile Number, IPF) is allowed. An organization may hold only one active IRACDA grant award at a time.

The application must be submitted by an eligible organization with a Unique Entity Identifier (UEI) and a unique NIH eRA Institutional Profile File (IPF) number. For institutions with multiple campuses, eligibility can be considered for an individual campus (e.g., main, satellite, etc.) as the applicant organization only if a UEI and a unique NIH eRA IPF number are established for the individual campus. For institutions that use one UEI or NIH IPF number for multiple campuses, eligibility as the applicant organization is determined for the campuses together.

The IRACDA award may not be transferred from one institution to another.

All other aspects of this Notice of Funding Opportunity remain the same.

Inquiries

Please direct all inquiries to:

Shakira Nelson, Ph.D.
National Institutes of General Medical Sciences (NIGMS)
Email: [email protected]

Edgardo Falcón-Morales, Ph.D.
National Institutes of General Medical Sciences (NIGMS)
Email: [email protected]